CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough
Drugmaker CSPC Pharma gets the green light to produce China’s first homegrown mRNA vaccine, but the breakthrough comes too late in the pandemic to impress investors Key Takeaways: News of…
CanSino’s Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?
The company’s Convidecia has received emergency-use authorization from the World Health Organization, becoming the third Chinese vaccine to get that nod Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted…
AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt
Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM…
FAST NEWS: Covid Vaccine Maker Sinovac’s Profit Skyrockets in First Financial Report for 2021
The latest: Sinovac Biotech Ltd. (SVA.US), maker of one of China’s three major Covid-19 vaccines, reported its revenue soared 161 times to $11 billion (70 billion yuan) in the first…
Greatly Transformed Sinovac Set to Reawaken on Wall Street?
Maker of the CoronaVac vaccine for Covid-19 could soon resume trading on the Nasdaq after a nearly three-year pause, following two key legal developments Key takeaways: Two key legal developments…
Pandemic Accelerates China’s Drive Into mRNA Treatments
Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases Key points: High efficacy rates in preventing Covid-19 spark rush by…
Recent Articles
RELATED ARTICLES
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK - Health Guard plans dual listing to fund HPV vaccine fight
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
